[
    {
        "Index": "ef0e4f95",
        "Question": "Should patients with RA on DMARDs who are in low disease activity gradually taper off DMARDs, abruptly withdraw DMARDs, or continue DMARDS at the same doses?",
        "P": "Patients with rheumatoid arthritis (RA) who are on Disease-Modifying Anti-Rheumatic Drugs (DMARDs) and in low disease activity",
        "I": "Gradually taper off DMARDs",
        "C": [
            "Abruptly withdraw DMARDs or continue DMARDs at the same doses"
        ],
        "O": {
            "Abruptly withdraw DMARDs or continue DMARDs at the same doses": [
                "Disease activity (follow up: range 9 months to 12 months; assessed with: DAS28-ESR)",
                "Flare (follow up: range 6 months to 12 months)",
                "Radiographic progression (follow up: range 9 months to 12 months; assessed with: mTSS)",
                "Fatigue (follow up: range 9 months to 12 months; assessed with: FACIT-F)",
                "Quality of Life (follow up: 9 months; assessed with: SF-36 PCS)",
                "Quality of Life (follow up: 9 months; assessed with: SF-36 MCS)",
                "Disability (follow up: 12 months; assessed with: HAQ-DI)",
                "Pain (follow up: 12 months; assessed with: VAS Pain)",
                "Withdrawal due to lack of efficacy (follow up: 12 months)",
                "Withdrawal due to adverse events (follow up: range 9 months to 12 months)",
                "Serious adverse events (follow up: range 9 months to 12 months)",
                "Malignancy (follow up: range 9 months to 12 months)",
                "Death (follow up: 12 months)"
            ]
        }
    }
]